Peptides
PT-141 (bremelanotide): where the prescription evidence applies
How does it work?
PT-141 is a common name for bremelanotide, a melanocortin-receptor agonist. The precise way it improves sexual desire is not fully established. Its prescription product, Vyleesi, is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder that causes distress and is not explained by another condition, relationship problem, or medication. It is not approved to improve sexual performance or for men or postmenopausal women. [1]
What do trials show?
The approved formulation was tested in controlled studies for that defined population and showed improvements in measures of desire and related distress. That outcome should not be generalized to all forms of low libido or to an untested research powder. [1]
Safety
The prescription label warns about temporary blood-pressure increases and heart-rate decreases, nausea, and focal hyperpigmentation. It is contraindicated with uncontrolled hypertension or known cardiovascular disease. The commercial sterile autoinjector has defined concentration and instructions; the catalog 10 mg vial does not inherit its regulatory review. [1]
PRESCRIPTION-LABEL CONTEXT
How much?
SOURCE CONTEXT
What it refers to
subcutaneously as needed at least 45 minutes before anticipated activity, no more than once in 24 hours, and more than eight doses per month is not recommended.
The FDA-labeled Vyleesi regimen is 1.75 mg subcutaneously as needed at least 45 minutes before anticipated activity, no more than once in 24 hours, and more than eight doses per month is not recommended. That is a prescribed dose for the approved device and indication, not a dosing instruction for this research vial. A clinician should assess suitability and supply an approved product where appropriate. [1]